In the prospective, observational GOULD (Getting to an Improved Understanding of Low‐Density Lipoprotein‐Cholesterol and Dyslipidemia Management) study, 92% of patients continued to receive PCSK9 inhibitors after 2 years.31 The gene discussed is PCSK9; the disease is metabolic syndrome.